TY - JOUR
T1 - Incidence of refractory cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation
AU - Jinnouchi, Fumiaki
AU - Mori, Yasuo
AU - Yoshimoto, Goichi
AU - Yamauchi, Takuji
AU - Nunomura, Takuya
AU - Yurino, Ayano
AU - Hayashi, Masayasu
AU - Yuda, Junichiro
AU - Shima, Takahiro
AU - Odawara, Jun
AU - Takashima, Shuichiro
AU - Kamezaki, Kenjiro
AU - Kato, Koji
AU - Miyamoto, Toshihiro
AU - Akashi, Koichi
AU - Takenaka, Katsuto
N1 - Funding Information:
This work was supported by JSPS KAKENHI (Grant No: 18H02840).
Publisher Copyright:
© 2021, Japanese Society of Hematology.
PY - 2022/1
Y1 - 2022/1
N2 - Post-transplant cytomegalovirus (CMV) disease can be almost completely avoided by current infection control procedures. However, CMV reactivation occurs in more than half of patients, and some patients can develop clinically resistant CMV infections. Whether resistance is due to the host’s immune status or a viral resistance mutation is challenging to confirm. Therefore, a prospective observational analysis of refractory CMV infection was conducted in 199 consecutive patients who received allogeneic hematopoietic stem cell transplantation at a single institution. Among them, 143 (72%) patients received anti-CMV drugs due to CMV reactivation, and only 17 (8.5%) exhibited refractory CMV infection. These patients had clinically refractory infection. However, viral genome analysis revealed that only one patient exhibited a mutation associated with the anti-CMV drug resistance. Clinical resistance was mainly correlated with host immune factors, and the incidence of resistance caused by gene mutations was low at the early stage after a transplantation.
AB - Post-transplant cytomegalovirus (CMV) disease can be almost completely avoided by current infection control procedures. However, CMV reactivation occurs in more than half of patients, and some patients can develop clinically resistant CMV infections. Whether resistance is due to the host’s immune status or a viral resistance mutation is challenging to confirm. Therefore, a prospective observational analysis of refractory CMV infection was conducted in 199 consecutive patients who received allogeneic hematopoietic stem cell transplantation at a single institution. Among them, 143 (72%) patients received anti-CMV drugs due to CMV reactivation, and only 17 (8.5%) exhibited refractory CMV infection. These patients had clinically refractory infection. However, viral genome analysis revealed that only one patient exhibited a mutation associated with the anti-CMV drug resistance. Clinical resistance was mainly correlated with host immune factors, and the incidence of resistance caused by gene mutations was low at the early stage after a transplantation.
UR - http://www.scopus.com/inward/record.url?scp=85116981234&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85116981234&partnerID=8YFLogxK
U2 - 10.1007/s12185-021-03218-3
DO - 10.1007/s12185-021-03218-3
M3 - Article
C2 - 34652633
AN - SCOPUS:85116981234
SN - 0925-5710
VL - 115
SP - 96
EP - 106
JO - International journal of hematology
JF - International journal of hematology
IS - 1
ER -